VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as VNP40101M and hydroxyurea, work in different
ways to stop cancer cells from dividing so they stop growing or die. Hydroxyurea may help
VNP40101M kill more cancer cells by making cancer cells more sensitive to the drug.
PURPOSE: This phase II trial is studying how well giving VNP40101M with hydroxyurea works in
treating patients with acute myelogenous leukemia or high-risk myelodysplasia.